Evidence map›Paper›PMID 35284987›Full record

ArticleJournal of clinical immunology2022

Health-Related Quality of Life in 91 Patients with X-Linked Agammaglobulinemia.

Katherine Altman, Chuan Zhou, Vivian Hernandez-Trujillo, Christopher Scalchunes, David J Rawlings, M Teresa de la Morena

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of clinical immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.6field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. The dilemma of X-linked agammaglobulinemia carriers.The journal of allergy and clinical immunology. Global · 2025
    Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Katherine AltmanDivision of Allergy and Immunology, University of Washington, Seattle, WA, 98101, USA.
Chuan ZhouDivision of General Pediatrics, School of Medicine, University of Washington, Seattle, WA, USA.
Vivian Hernandez-TrujilloDivision of Allergy and Immunology, Nicklaus Children's Hospital, Miami, FL, USA.
Christopher ScalchunesImmune Deficiency Foundation, 110 West Road, Suite 300, Towson, MD, 21204, USA.
David J RawlingsDivision of Immunology, Department of Pediatrics, University of Washington, Seattle, WA, 98101, USA.
M Teresa de la MorenaDivision of Immunology, Department of Pediatrics, University of Washington, Seattle, WA, 98101, USA. maite.delamorena@seattlechildrens.org.
University of Washington · USBaptist Hospital of Miami · USImmune Deficiency Foundation · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeX-linked agammaglobulinemia (XLA) is a primary immunodeficiency (PID) caused by a defect in the gene encoding for Bruton tyrosine kinase (BTK). In the absence of a functional BTK, patients have low or absent circulating B cells and low or absent serum immunoglobulin. Despite gammaglobulin replacement and prompt use of antimicrobial agents, patients with XLA continue to experience infectious and non-infectious complications throughout their lifetime. The purpose of this study was to understand self-perceived health status of US-based patients with XLA, and examine the associations amongst clinical characteristics, treatment experience, and quality of life (QoL).

methodsA 46 and 68 question survey, developed by the Immune Deficiency Foundation (IDF) and a Short Form-12item v2® (SF-12v2®) for adults and SF-10™ for children to assess QoL, were mailed by IDF to patients in 2017 and 2018. Those that self-identified as having XLA or males with agammaglobulinemia were selected for analysis. Mean physical and mental composite scores (PCS and MCS) from SF-12v2® and mean physical health component (PHS) and psychological health summary (PSS) from SF-10™ scores were compared to the US normative data.

resultsNinety-one patients completed the surveys: 58 (63.7%) adults and 33 (36.3%) children. For the combined surveys, the overall median age at time of the survey was 28.5 years (yrs); Inter-Quartile-Range (IQR) 13-49.5 yrs; the median age at diagnosis was 2 yrs (IQR = 0-4 yrs) and the median number of years with XLA diagnosis was 23 (IQR 10.75-40yrs). Amongst adult patients, physical scores were noted to be below the general adult population but did not reach statistical significance. In contrast, 2 or more chronic conditions impacted both physical and mental QoL (p < .001) and hospitalization was associated with significantly decreased physical health QoL (p < .001); three or more infections in the past 12 months exhibited impact on physical health although was not found to be statistically significant. Adult patients with public insurance fared worse in mental health domains compared to those with combined public and private or those with private alone (p = 0.001). Employment status did not impact QoL. None of these variables met statistical significance nor demonstrated impact within the pediatric population in either physical or mental domains of health.

conclusionOur study provides further insight into what factors impact both physical and mental domains of health amongst patients with XLA. Early detection to prevent the development of associated morbidity, as well as vigilant care to prevent hospitalizations and infections, can limit the impact this disease may have on the overall well-being of XLA patients.

Indexed as

AgammaglobulinemiaGenetic Diseases, X-LinkedAdultChildHumansImmunoglobulins, IntravenousMaleMutationQuality of LifeImmunoglobulins, IntravenousQuality of LifeXLAX-linked agammaglobulinemia

Identifiers

PMID35284987
OpenAlexW4221011790

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.